GW-856464

Details

Stereochemistry	ABSOLUTE
Molecular Formula	C23H20ClN3O3S
Molecular Weight	453.941
Optical Activity	UNSPECIFIED
Defined Stereocenters	1 / 1
E/Z Centers	0
Charge	0

SHOW SMILES / InChI

Structure Search

SMILES

COC1=C(C=CC(=C1)N2C=NC3=C(SC(=C3)C4=CC=C(Cl)C=C4)C2=O)N5CC[C@@H](O)C5

InChI

InChIKey=JOAYEJZDGOLEDZ-QGZVFWFLSA-N

InChI=1S/C23H20ClN3O3S/c1-30-20-10-16(6-7-19(20)26-9-8-17(28)12-26)27-13-25-18-11-21(31-22(18)23(27)29)14-2-4-15(24)5-3-14/h2-7,10-11,13,17,28H,8-9,12H2,1H3/t17-/m1/s1

HIDE SMILES / InChI

Molecular Formula	C23H20ClN3O3S
Molecular Weight	453.941
Charge	0
Count

Stereochemistry	ABSOLUTE
Additional Stereochemistry	No
Defined Stereocenters	1 / 1
E/Z Centers	0
Optical Activity	UNSPECIFIED

Approval Year

Substance Class	Chemical Created by `admin` on `Tue Apr 01 16:30:56 GMT 2025` Edited by `admin` on `Tue Apr 01 16:30:56 GMT 2025`
Record UNII	2BN5Z6HFX3
Record Status	`Validated (UNII)`
Record Version

Download

Name

Type

Language

6-(4-CHLOROPHENYL)-3-(4-((3R)-3-HYDROXYPYRROLIDIN-1-YL)-3-METHOXY-PHENYL)THIENO(3,2-D)PYRIMIDIN-4-ONE

Preferred Name

English

GW-856464

Common Name

English

(R)-6-(4-CHLOROPHENYL)-3-(4-(3-HYDROXYPYRROLIDIN-1-YL)-3-METHOXYPHENYL)THIENO(3,2-D)PYRIMIDIN-4(3H)-ONE

Systematic Name

English

GW856464

Code

English

THIENO(3,2-D)PYRIMIDIN-4(3H)-ONE, 6-(4-CHLOROPHENYL)-3-(4-((3R)-3-HYDROXY-1-PYRROLIDINYL)-3-METHOXYPHENYL)-

Systematic Name

English

Code System Code Type Description

FDA UNII

2BN5Z6HFX3

Created by admin on Tue Apr 01 16:30:56 GMT 2025 , Edited by admin on Tue Apr 01 16:30:56 GMT 2025

PRIMARY

PUBCHEM

11419640

Created by admin on Tue Apr 01 16:30:56 GMT 2025 , Edited by admin on Tue Apr 01 16:30:56 GMT 2025

PRIMARY

CAS

851690-21-6

Created by admin on Tue Apr 01 16:30:56 GMT 2025 , Edited by admin on Tue Apr 01 16:30:56 GMT 2025

PRIMARY

Related Record Type Details


					2BN5Z6HFX3

GW-856464

ACTIVE MOIETY

Comments:

Class: Pyrimidinone, Pyrrolidine, Small molecule; Mechanism of Action: MCHR1 protein inhibitor Highest Development Phase: No development reported for Obesity; Most Recent Events: 18 Apr 2011 No development reported - Preclinical for Obesity in USA (PO), 01 Sep 2010 Preclinical development is ongoing in USA, 31 Oct 2007 Data presented at the 2007 Annual Meeting of the North American Association for the Study of Obesity (NAASO-2007) added to the Obesity pharmacodynamics section


					2BN5Z6HFX3

GW-856464

ACTIVE MOIETY

Comments:

The observations that mice with overexpression of MCH1-R are obese, MCH1-R knockout animals become lean and can develop a hypophagia (208,209) and leaness may occur also in consequence to ablation of melanin-concentrating hormone neurons (210) accelerated the efforts in search for suitable antagonistic agents up to date. Among these GW 856464 (211), AMG076 (212)and NGD-4715 (213) achieved phase 1 clinical investigations.